Wei Zhu

Wei Zhu

Auto-generated profile, based on publicly available information

Wei Zhu

Department of Pathology, Xiangya Hospital, Central South University, Changsha, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
DXDing Xiao
Ding Xiao
TZTing Zeng
Ting Zeng
WZWei Zhu
Wei Zhu
ZYZheng-Zheng Yu
Zheng-Zheng Yu
WHWei Huang
Wei Huang
ZXZhi-Qiang Xiao
Zhi-Qiang Xiao
The deregulation of Annexin A1 (ANXA1), a regulator of inflammation and immunity, leads to cancer growth and metastasis. However, whether ANXA1 is involved in cancer immunosuppression is still unclear. Here, we report that ANXA1 knockdown (i) dramatically downregulates programmed cell death-ligand 1 (PD-L1) expression in breast cancer, lung cancer, and melanoma cells; (ii) promotes T cell–mediated killing of cancer cells in vitro; and (iii) inhibits cancer immune escape in immune-competent mice via downregulating PD-L1 expression and increasing the number and killing activity of CD8+ T cells. Mechanistically, ANXA1 functioned as a sponge molecule for interaction of PARP1 and Stat3. Specifically, binding of ANXA1 to PARP1 decreased PARP1’s binding to Stat3, which reduced poly(ADP-ribosyl)ation and dephosphorylation of Stat3 and thus, increased Stat3’s transcriptional activity, leading to transcriptionally upregulated expression of PD-L1 in multiple cancer cells. In clinical samples, expression of ANXA1 and PD-L1 was significantly higher in breast cancer, non–small cell lung cancer, and skin cutaneous melanoma compared with corresponding normal tissues and positively correlated in cancer tissues. Moreover, using both ANXA1 and PD-L1 proteins for predicting efficacy of anti–PD-1 immunotherapy and patient prognosis was superior to using individual proteins. Our data suggest that ANXA1 promotes cancer immune escape via binding PARP1 and upregulating Stat3-induced expression of PD-L1, that ANXA1 is a potential new target for cancer immunotherapy, and combination of ANXA1 and PD-L1 expression is a potential marker for predicting efficacy of anti–PD-1 immunotherapy in multiple cancers.

1 April 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
DWDi Wu
Di Wu
TZTing Zeng
Ting Zeng
RLRuo-Huang Lu
Ruo-Huang Lu
WZWei Zhu
Wei Zhu
QWQi Wen
Qi Wen
JPJinwu Peng
Jinwu Peng
Background: Immune checkpoint inhibitors (ICIs) therapy targeting programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) shows promising clinical benefits in non-small cell lung cancer (NSCLC). However, the relatively low response rate highlights the need to elucidate the regulatory mechanism of PD-L1 expression, and develop an alternative strategy to target PD-1/PD-L1 immune checkpoint pathway. Our study focuses on the role and mechanism of ubiquitin-specific protease 15 (USP15) and its derived peptide U10 on NSCLC immune evasion. Methods: USP15 as PD-L1’s deubiquitinase was identified by screening a human USP complementary DNA (cDNA) library. The role and mechanism of USP15 and its derived peptide U10 on PD-L1 stability in NSCLC cells were analyzed. T cell-mediated tumor cell killing activity and a syngeneic mouse NSCLC model were used to assess the influence of USP15 and U10 on NSCLC immune evasion. The antitumor effect of U10 in combination with PD-1 monoclonal antibody (mAb) via suppressing NSCLC immune evasion was also evaluated in mice. The expression and clinicopathological significance of USP15 and PD-L1 in cancer tissues were evaluated by immunohistochemistry. Results: We identify USP15 as a novel deubiquitinase of PD-L1. Mechanistically, USP15 binds and stabilizes PD-L1 in NSCLC cells by inhibiting its ubiquitination and degradation. Functionally, USP15 inhibits T cell ability of killing NSCLC cells in vitro, and promotes NSCLC immune evasion in mice via decreasing the population and activation of CD8 + T cells in the tumor microenvironment. Based on the interacting regions of USP15 and PD-L1, we develop a 10 amino acid-long USP15-derived peptide U10, which successfully degrades PD-L1 via disrupting USP15 and PD-L1 interaction, dramatically suppresses NSCLC immune escape in vitro and in mice, and enhances the anti-NSCLC effect of PD-1 mAb in mice. Moreover, the expression levels of USP15 and PD-L1 are significantly higher in NSCLC than those in normal lung tissues and are positively correlated. The combination of USP15 and PD-L1 proteins was superior to individual proteins for predicting the efficacy of PD-1 mAb immunotherapy and patient prognosis in NSCLC. Conclusion: Our findings reveal a critical role for USP15 in PD-L1 stability regulation and NSCLC immune escape and develop a novel peptide as an alternative strategy for ICIs therapy of NSCLC.

5 June 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
TZTing Zeng
Ting Zeng
DXDing Xiao
Ding Xiao
WZWei Zhu
Wei Zhu
DWDi Wu
Di Wu
HYHong Yi
Hong Yi
JPJinwu Peng
Jinwu Peng
Radioresistance is a serious obstacle to successful nasopharyngeal carcinoma (NPC) treatment. Annexin A1 (ANXA1) is associated with EGFR and is involved in EGFR-promoting tumors, but the mechanisms of ANXA1-stabilizing EGFR and its effect on NPC radioresistance are unclear. In this study, we report that ANXA1 competes with the E3 ubiquitin ligase Cbl for binding to EGFR and increases its stability by inhibiting Cbl-mediated EGFR ubiquitination degradation in NPC cells. ANXA1 increases in vitro and in vivo NPC cell radioresistance by stabilizing EGFR. Expression levels of ANXA1 and EGFR are positively correlated in NPC tissues and are significantly higher in the radioresistant NPC tissues than in the radiosensitive NPC tissues. Patients with NPC with high expression of both proteins have poorer overall survival and disease-free survival relative to patients with high expression of one protein alone, and a combination of ANXA1 and EGFR predicts NPC radiosensitivity superior to that of the individual proteins. Based on the amino acid residues of ANXA1 responsible for binding to EGFR, we developed a nine amino acid–long ANXA1-derived peptide (HDMNKVLDL), which disrupts the connection of ANXA1 with EGFR, successfully downregulates EGFR expression, and dramatically increases NPC cell radiosensitivity in vitro and in mice. Our findings suggest that ANXA1 promotes NPC radioresistance by binding to and stabilizing EGFR, and we present a strategy for targeting EGFR degradation and NPC radiosensitization with a peptide.

1 October 2025
Verified
Other
Open access
PDF file
TZTing Zeng
Ting Zeng
DXDing Xiao
Ding Xiao
WZWei Zhu
Wei Zhu
DWDi Wu
Di Wu
HYHong Yi
Hong Yi
JPJinwu Peng
Jinwu Peng
Figure S2. Mapping of the binding regions of ANXA1 and EGFR

1 October 2025
Verified
Other
Open access
PDF file
TZTing Zeng
Ting Zeng
DXDing Xiao
Ding Xiao
WZWei Zhu
Wei Zhu
DWDi Wu
Di Wu
HYHong Yi
Hong Yi
JPJinwu Peng
Jinwu Peng
Figure S5. Immunohistochemistry (IHC) showing the expression levels of ANXA1 and EGFR in the subcutaneous xenografts from HK1 nasopharyngeal carcinoma (NPC) cells with ANXA1 knockdown, HK1 NPC cells with ANXA1 knockdown and EGFR overexpression and shNC control HK1 cells

1 October 2025
Verified
Other
Open access
PDF file
TZTing Zeng
Ting Zeng
DXDing Xiao
Ding Xiao
WZWei Zhu
Wei Zhu
DWDi Wu
Di Wu
HYHong Yi
Hong Yi
JPJinwu Peng
Jinwu Peng
Figure S4. ANXA1 increases in vitro NPC cell radioresistance via binding and stabilizing EGFR